Researchers at Oregon Health & Science University (OHSU) have identified the enzyme cell‑migration‑inducing and hyaluronan‑binding protein (CEMIP) as a key player in the failure of myelin repair across several neurological disorders, including multiple sclerosis (MS), stroke, traumatic brain injury and Alzheimer’s disease. The findings, published in ASN Neuro, extend earlier work that linked CEMIP‑mediated hyaluronic‑acid breakdown to disrupted central‑nervous‑system (CNS) regeneration.
Study Findings
The OHSU team examined CEMIP expression in three experimental systems: cultured neural cells, mouse models of demyelination, and post‑mortem human brain tissue from donors with MS. In mice engineered to lack the ability to remyelinate, CEMIP levels surged in lesions where myelin was lost. Similarly, human MS brain samples showed markedly higher CEMIP staining in perilesional zones compared with unaffected tissue.
Mechanistically, CEMIP cleaves high‑molecular‑weight hyaluronic acid (HA) into low‑molecular‑weight fragments. While HA accumulation is a normal response to injury, the fragments act as “danger signals” that activate Toll‑like receptor 4 (TLR4) and downstream pathways that inhibit the maturation of oligodendrocyte progenitor cells (OPCs). Without mature oligodendrocytes, new myelin sheaths cannot form, prolonging axonal damage.
To test whether inhibiting CEMIP could restore remyelination, the researchers administered a natural compound derived from dahlias—previously shown to suppress CEMIP activity—in demyelinated mice. Treated animals displayed a 30 % increase in OPC differentiation and a modest, but statistically significant, improvement in conduction velocity, indicating functional myelin recovery.
Expert Commentary
Senior author Larry Sherman, Ph.D., professor in OHSU’s Division of Neuroscience, emphasized that “CEMIP represents a molecular brake on repair. By releasing that brake, we may be able to tip the balance toward regeneration in diseases where myelin loss drives disability.”
Dr. Ben Emery, a neuroscientist who led a parallel study on the DLK‑mediated neurodegeneration pathway, noted that “targeting distinct pathways that converge on neuronal survival—whether DLK or CEMIP—offers complementary strategies for preserving axons in MS” [news.ohsu.edu].
Independent experts agree that the enzyme’s dual role—facilitating early inflammatory signaling while impeding long‑term repair—mirrors findings from a 2018 NIH‑funded study that identified hyaluronic‑acid fragments as “roadblocks” to white‑matter healing [ScienceDaily].
Implications for Patients and Public Health
Myelin damage underlies the clinical progression of MS, which the World Health Organization estimates affects roughly 3 million people worldwide [WHO]. In stroke and traumatic brain injury, secondary demyelination amplifies neurological deficits and hampers rehabilitation. Likewise, recent imaging studies link myelin loss in the hippocampus to cognitive decline in Alzheimer’s disease.
If CEMIP inhibition proves safe and effective in humans, it could complement existing disease‑modifying therapies for MS—such as B‑cell depleting agents—by directly enhancing repair rather than merely suppressing inflammation. For stroke survivors, a drug that accelerates remyelination might reduce long‑term disability, aligning with the U.S. Centers for Disease Control and Prevention’s emphasis on secondary prevention of post‑stroke cognitive impairment [CDC].
Next Steps in Research
While the dahlias‑derived inhibitor showed promise in animal models, it has not yet entered clinical trials. The OHSU researchers plan to refine the compound’s pharmacokinetic profile and assess safety in rodent toxicology studies before moving to Phase I trials.
Concurrently, collaborations are forming to test whether combining CEMIP inhibition with agents that block the DLK pathway—shown to protect neurons in chronic demyelination—produces additive benefits. Such combination strategies echo a broader trend in neuro‑degenerative research: targeting both neuroinflammation and repair mechanisms to achieve disease modification.
Regulatory agencies are closely monitoring these developments because of the high unmet need for therapies that restore myelin. The National Institute of Neurological Disorders and Stroke (NINDS) has pledged additional funding for “myelin‑repair” projects, reflecting the strategic priority of translating basic discoveries into patient‑focused interventions [NINDS].
Why This Matters
Understanding and modulating CEMIP could open a new therapeutic avenue that not only slows disease progression but also actively repairs damaged neural circuitry—a critical advance for millions living with MS, stroke, traumatic brain injury, and Alzheimer’s disease.
Read more on Globally Pulse Health for updates on emerging neuro‑repair therapies.
